CY1116182T1 - Ενωσεις ως β1-ανταγωνιστες της βραδυκινινης - Google Patents

Ενωσεις ως β1-ανταγωνιστες της βραδυκινινης

Info

Publication number
CY1116182T1
CY1116182T1 CY20151100211T CY151100211T CY1116182T1 CY 1116182 T1 CY1116182 T1 CY 1116182T1 CY 20151100211 T CY20151100211 T CY 20151100211T CY 151100211 T CY151100211 T CY 151100211T CY 1116182 T1 CY1116182 T1 CY 1116182T1
Authority
CY
Cyprus
Prior art keywords
compounds
bradykinin
compressors
production
salts
Prior art date
Application number
CY20151100211T
Other languages
English (en)
Inventor
Norbert Hauel
Angelo Ceci
Henri Doods
Ingo Konetzki
Juergen Mack
Henning Priepke
Annette Schuler-Metz
Rainer Walter
Dieter Wiedenmayer
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2010/052232 external-priority patent/WO2010097372A1/de
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of CY1116182T1 publication Critical patent/CY1116182T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/54—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings
    • C07C211/56—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Αντικείμενο της παρούσας εφεύρεσης είναι οι ενώσεις του γενικού τύπου (I), στον οποίο n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 και Χ ορίζονται όπως περιγράφεται παρακάτω, τα εναντιομερή τους, τα διαστερεοϊσομερή τους, τα μείγματα τους και τα άλατα τους, ιδιαιτέρως τα φυσιολογικά συμβατά άλατα τους με οργανικά ή ανόργανα οξέα ή βάσεις, τα οποία έχουν πολύτιμες ιδιότητες, η παραγωγή τους, φάρμακα, τα οποία περιέχουν τις φαρμακολογικά δραστικές ενώσεις, η παραγωγή τους και η χρήση τους.
CY20151100211T 2010-02-23 2015-03-02 Ενωσεις ως β1-ανταγωνιστες της βραδυκινινης CY1116182T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2010/052232 WO2010097372A1 (de) 2009-02-26 2010-02-23 Verbindungen als bradykinin-b1-antagonisten
EP11705858.6A EP2539323B3 (de) 2010-02-23 2011-02-21 Verbindungen als Bradykinin-B1-Antagonisten

Publications (1)

Publication Number Publication Date
CY1116182T1 true CY1116182T1 (el) 2017-02-08

Family

ID=43981434

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100211T CY1116182T1 (el) 2010-02-23 2015-03-02 Ενωσεις ως β1-ανταγωνιστες της βραδυκινινης

Country Status (23)

Country Link
EP (1) EP2539323B3 (el)
JP (1) JP5603955B2 (el)
KR (1) KR101843341B1 (el)
CN (2) CN102781916B (el)
AP (1) AP3218A (el)
AR (1) AR080249A1 (el)
AU (1) AU2011219885C1 (el)
CA (1) CA2790952C (el)
CY (1) CY1116182T1 (el)
DK (1) DK2539323T6 (el)
ES (1) ES2531663T7 (el)
HK (1) HK1175171A1 (el)
IL (1) IL220680A (el)
MA (1) MA34008B1 (el)
MX (1) MX2012009224A (el)
NZ (1) NZ601194A (el)
PE (1) PE20121805A1 (el)
PL (1) PL2539323T6 (el)
PT (1) PT2539323E (el)
SG (1) SG183336A1 (el)
SI (1) SI2539323T1 (el)
TW (1) TWI499589B (el)
WO (1) WO2011104203A1 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007034620A1 (de) 2007-07-25 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue B1-Antagonisten
ATE550321T1 (de) 2007-08-29 2012-04-15 Boehringer Ingelheim Int Neue bradykinin b1-antagonisten
KR101843341B1 (ko) 2010-02-23 2018-03-30 베링거 인겔하임 인터내셔날 게엠베하 브라디키닌 ｂ１ 길항제로서의 화합물
US8937073B2 (en) 2010-08-20 2015-01-20 Boehringer Ingelheim International Gmbh Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists
WO2012022794A1 (de) * 2010-08-20 2012-02-23 Boehringer Ingelheim International Gmbh Pyridazinderivative als bradykinin b1 rezeptor antagonsiten
JP7376582B2 (ja) * 2018-10-22 2023-11-08 イーオーイー オレオ ゲーエムベーハー 成形体への圧縮を目的とした粉末材料用添加剤
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919343B2 (en) * 2002-02-08 2005-07-19 Merck & Co., Inc. N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives
CA2495914A1 (en) * 2002-08-29 2004-03-11 Merck & Co., Inc. N-biarylmethyl aminocycloalkanecarboxamide derivatives
EP1654232A4 (en) * 2003-08-07 2008-11-12 Merck & Co Inc N- (BIARYLMETHYL) AMINOCYCLOPROPANECARBOXAMIDES WITH SULFONYL SUBSTITUTION
JP2007526311A (ja) 2004-03-02 2007-09-13 メルク　エンド　カムパニー　インコーポレーテッド ブラジキニンアンタゴニストとしてのアミノシクロプロパンカルボキサミド誘導体
AU2006245770A1 (en) 2005-05-11 2006-11-16 Nycomed Gmbh Combination of the PDE4 inhibitor roflumilast and a tetrahydrobiopterin derivative
HUP0600809A3 (en) * 2006-10-27 2008-09-29 Richter Gedeon Nyrt New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
WO2010097372A1 (de) * 2009-02-26 2010-09-02 Boehringer Ingelheim International Gmbh Verbindungen als bradykinin-b1-antagonisten
KR101843341B1 (ko) 2010-02-23 2018-03-30 베링거 인겔하임 인터내셔날 게엠베하 브라디키닌 ｂ１ 길항제로서의 화합물

Also Published As

Publication number Publication date
CN103980258A (zh) 2014-08-13
ES2531663T7 (es) 2018-02-13
CA2790952C (en) 2017-07-04
KR20130025864A (ko) 2013-03-12
IL220680A (en) 2015-08-31
WO2011104203A1 (de) 2011-09-01
MX2012009224A (es) 2012-08-23
HK1175171A1 (en) 2013-06-28
AP2012006330A0 (en) 2012-06-30
DK2539323T6 (en) 2018-01-02
AU2011219885C1 (en) 2017-06-29
NZ601194A (en) 2014-10-31
MA34008B1 (fr) 2013-02-01
EP2539323B1 (de) 2014-12-03
CN103980258B (zh) 2016-09-07
IL220680A0 (en) 2012-08-30
CN102781916A (zh) 2012-11-14
JP5603955B2 (ja) 2014-10-08
AU2011219885A1 (en) 2012-08-02
AP3218A (en) 2015-04-30
PT2539323E (pt) 2015-02-16
JP2013519710A (ja) 2013-05-30
SI2539323T1 (sl) 2015-03-31
PL2539323T6 (pl) 2018-05-30
KR101843341B1 (ko) 2018-03-30
DK2539323T3 (da) 2015-02-23
ES2531663T3 (es) 2015-03-18
AR080249A1 (es) 2012-03-21
AU2011219885B2 (en) 2015-10-15
EP2539323A1 (de) 2013-01-02
CN102781916B (zh) 2014-06-25
PL2539323T3 (pl) 2015-05-29
SG183336A1 (en) 2012-09-27
CA2790952A1 (en) 2011-09-01
EP2539323B3 (de) 2017-10-04
PE20121805A1 (es) 2013-01-23
TWI499589B (zh) 2015-09-11
TW201141848A (en) 2011-12-01

Similar Documents

Publication Publication Date Title
CY1114130T1 (el) Ενωσεις ως β1-ανταγωνιστες της βραδυκινινης
CY1116182T1 (el) Ενωσεις ως β1-ανταγωνιστες της βραδυκινινης
CY1118656T1 (el) Παραγωγο πυριδονης
CY1123237T1 (el) Αρυλο και ετεροαρυλο συμπυκνωμενες λακταμες
CY1115945T1 (el) Παραγωγα πυραζολοκινολινονης, η παρασκευη τους και η θεραπευτικη τους χρηση
CY1118129T1 (el) 5-αλκυνυλ-πυριμιδινες
CY1123524T1 (el) Υποκατεστημενα χρωμανια και μεθοδος χρησης
CY1121804T1 (el) Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους
CY1120207T1 (el) Διαδικασιες για τη συνθεση ενωσεων διαρυλοθειοϋδαντοϊνης και διαρυλυδαντοϊνης
CY1124022T1 (el) Σχημα χορηγησης για νιτροκατεχολες
CY1109644T1 (el) 2,4-διαμινο-πυριμιδινες ως αναστολεις audora
CY1122610T1 (el) Αλκοξυ πυραζολια ως ενεργοποιητες διαλυτης γουανυλικης κυκλασης
CY1119134T1 (el) Υποδοχεις της νεπριλυσινης
CY1119842T1 (el) Συντηγμενες τρικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις ιντεγκρασης hiv
CY1119544T1 (el) Πολυκυκλικες ενωσεις καραβαμοϋλοπυριδονης και χρηση αυτων στη θεραπεια λοιμωξεων απο hiv
CY1119953T1 (el) Yποκατεστημενες πυριδοπυραζινες ως προτυποι syk ανοστολεις
PH12014502788B1 (en) ARYL SULTAM DERIVATIVES AS RORc MODULATORS
CY1119620T1 (el) Αναστολεις νεπριλυσινης
CY1121677T1 (el) Ενωσεις διμεθυλοβενζοϊκου οξεος
CY1117200T1 (el) Παραγωγα βενζυλαμινης ως αναστολεις καλλικρεϊνης πλασματος
CY1117105T1 (el) Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao
CY1116984T1 (el) ΠΑΡΑΓΩΓΑ [1,2,3]ΤΡΙΑΖΟΛΟ[4,5-d]ΠΥΡΙΜΙΔΙΝΗΣ ΩΣ ΑΓΩΝΙΣΤΕΣ ΥΠΟΔΟΧΕΑ ΚΑΝΝΑΒΙΝΟΕΙΔΩΝ 2
CY1108183T1 (el) Θειαζολυλο-διυδρο-ινδαζολια
CY1115933T1 (el) Διϋποκατεστημενες ενωσεις τετραϋδροφουρανυλιου ως ανταγωνιστες toy β1-υποδοχεα βραδυκινινης
CY1119022T1 (el) Παραγωγα ν-προπ-2-υνυλ καρβοξαμιδιου και χρηση αυτων ως ανταγωνιστες του trpa1